The identification of small molecules that target specific CFTR variants has ushered in a
new era of treatment for cystic fibrosis (CF), yet optimal, individualized treatment of CF will …

The existence of pleiotropy in disorders with multi-organ involvement can suggest therapeutic
targets that could ameliorate overall disease severity. Here we assessed pleiotropy of …

Cystic fibrosis is realizing the promise of personalized medicine. Recent advances in drug
development that target the causal CFTR directly result in lung function improvement, but …

Cystic Fibrosis (CF) exhibits morbidity in several organs, including progressive lung disease
in all patients and intestinal obstruction at birth (meconium ileus) in ~15%. Individuals with …

Circulating immunoreactive trypsinogen (IRT), a biomarker of exocrine pancreatic disease
in cystic fibrosis (CF), is elevated in most CF newborns. In those with severe CF …

Objectives To test the hypothesis that multiple constituents of the apical plasma membrane
residing alongside the causal cystic fibrosis (CF) transmembrane conductance regulator …

Gene-based, pathway, and other multivariate association methods are motivated by the
possibility of GxG and GxE interactions; however, accounting for such interactions is limited by …

Genome-wide association studies (GWAS) have primarily identified trait-associated loci in
the non-coding genome. Colocalization analyses of SNP associations from GWAS with …

Mathematical models for the tumour control probability (TCP) are used to estimate the expected
success of radiation treatment protocols of cancer. There are several TCP models in the …

Purpose Cystic fibrosis (CF), caused by pathogenic variants in the CF transmembrane
conductance regulator (CFTR), affects multiple organs including the exocrine pancreas, which is a …